Home Cart Sign in  
Chemical Structure| 484049-04-9 Chemical Structure| 484049-04-9

Structure of DPH
CAS No.: 484049-04-9

Chemical Structure| 484049-04-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

DPH is a potent cell permeable c-Abl activator, which displays potent enzymatic and cellular activity in stimulating c-Abl activation.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of DPH

CAS No. :484049-04-9
Formula : C18H13FN4O2
M.W : 336.32
SMILES Code : O=C1NC(C(C2=CN(C3=CC=CC=C3)N=C2C4=CC=C(F)C=C4)N1)=O
MDL No. :MFCD03268950

Safety of DPH

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

Related Pathways of DPH

RTK

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Neonatal rat ventricular myocytes 250 or 500 nM 48 hours To study the effects of sophocarpine on sodium current, results showed that sophocarpine significantly inhibited sodium current. PMC6525474
HEK293T cells 500 nM To evaluate the effect of ACBI1 on SMARCA4 protein levels in HEK293T cells, results showed that ACBI1 treatment led to a reduction in SMARCA4 protein levels. PMC6525474
4T1 cells 10 µg/mL 24 hours To evaluate the cellular uptake and antitumor effect of PP@T, results showed that PP@T significantly enhanced oxidative stress and apoptosis under ultrasound irradiation. PMC11186293
Mouse bone-marrow-derived macrophages 2 × 10^-6 M 1 min Measured membrane fluidity, showing the same fluidity in endocytosed membrane as in the plasma membrane PMC2120073
L929 mouse fibroblasts 2 × 10^-6 M 10 s to 90 min Investigated TMA-DPH as a marker for the endocytic pathway, showing its internalization from the cell periphery to perinuclear regions without noticeable loss in fluorescence intensity PMC2120073
HepG2 cells 10 μM DPH 30 minutes Evaluate the effect of SR9009 on BMAL1 mRNA expression PMC9813371

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6J mice TMPD-induced systemic lupus erythematosus model Intraperitoneal injection 0.5 mL TMPD Single injection, monitored for 6 months To investigate the role of FBXW7 in TMPD-induced systemic lupus erythematosus, results showed that FBXW7 deficiency attenuated immune complex deposition and nephritis. PMC6269436
Mice DSS-induced colitis model Intraperitoneal injection 70 mg/kg Once daily for 12 days DPH treatment significantly attenuated DSS-induced colitis symptoms, characterized by reduced weight loss, increased colon length, and decreased immunologic injury. PMC8104877
Mice Pressure overload model Oral gavage 30 mg/kg/day Once daily for 8 weeks Improves cardiac function, reduces fibrosis gene expression and interstitial fibrosis PMC6525474
BALB/c female mice 4T1 cell xenograft model Intravenous injection Every two days for 9 days M(I + D)PH treatment significantly inhibited tumor growth, reduced tumor weight, and increased infiltration of CD3+CD8+ T cells and enhanced DC maturation. PMC11186293
NSG mice Leukemia xenografts Intravenously 0.4 mg/kg Every other day for three doses To study resistance to Moxetumomab pasudotox and prevention by 5-azacytidine PMC5828592

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.97mL

0.59mL

0.30mL

14.87mL

2.97mL

1.49mL

29.73mL

5.95mL

2.97mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories